Zev Wainberg, MD, MSc
Zev Wainberg, MD, MSc, is a Professor of Medicine in the Division of Hematology and Oncology at the University of California, Los Angeles (UCLA). He is also the Co-Director of the Gastrointestinal Oncology Program at UCLA and the Santa Monica Cancer Center. Dr. Wainberg’s clinical interests include the development and testing of new targeted therapies for the treatment of colon cancer, gastric cancer and esophageal cancer.
Articles by Zev Wainberg, MD, MSc
The panel covers ASPEN-O6 results, excitement around ADCs in late-line HER-2 and Claudin-positive cancers, and more.
The panel considers tislelizumab amid existing PD-1 inhibitors, zolbetuximab for Claudin-positive patients, and more.
The panel covers updates on 1L treatments for metastatic gastric cancer, including the recent approval of tislelizumab.
The panel explores advancements in early-stage esophageal cancer, emphasizing the paradigm shift toward FLOT chemotherapy.
Personalized Care in Gastric and Esophageal Cancers: Biomarkers, Diagnosis, and Treatment Approaches
The panel focuses on the management of gastroesophageal cancers, highlighting differences in presentations across regions.
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Drs. Wainberg and Uboha highlight exciting developments set to occur at the ASCO Meeting, including ESOPEC and ARC-9.
Drs. Wainberg and Uboha discuss updated results from the FIGHT trial, noting improved OS in gastric cancer/GEJ cancer.
Dr. Wainberg provides insight on the NAPOLI-3 study that compared NALIRIFOX against nab-paclitaxel plus gemcitabine.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.